Aurora B
Aurora B (AURKB) is a mitotic serine/threonine kinase and the enzymatic core of the chromosomal passenger complex (CPC), which includes INCENP, Survivin, and Borealin[1]. Mechanistically, the CPC guides Aurora B through mitosis to control chromosome alignment, histone modification, kinetochore-microtubule error correction, spindle checkpoint signaling, and cytokinesis[1][2]. Therefore, Aurora B activity supports faithful chromosome segregation by releasing incorrect kinetochore-microtubule attachments, while reduced activity increases chromosome missegregation and aneuploid-cell generation[2]. In disease models, Aurora B deregulation or overexpression appears in several tumors, and studies in hepatocellular carcinoma, oral squamous cell carcinoma, prostate carcinoma, and glioblastoma connect Aurora B activity with recurrence, prognosis, tumor growth, or mitotic disruption[3][4][5][6]. Compared with related isoforms, Aurora A localizes to spindle poles and regulates mitotic entry, centrosome maturation, and spindle assembly, whereas Aurora B localizes with the CPC from inner centromeres to the spindle midzone and midbody[7]. Aurora C can act as a chromosomal passenger protein and complement Aurora B in mitotic cells, but Aurora B shows preferential INCENP binding and earlier M-phase expression[8]. For experimental applications, Aurora B or pan-Aurora inhibitors such as VX-680, AMG900, and danusertib help dissect metaphase-anaphase transition, cytokinetic initiation, mitotic progression, and cancer-cell proliferation[6][9][10].
References:
- [1]. Vader G, et al. The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol. 2006 Jun 19;173(6):833-7. [Content Brief]
- [2]. Abe Y, et al. System-level deficiencies in Aurora B control in cancers. Cell Cycle. 2016 Aug 17;15(16):2091-2092. [Content Brief]
- [3]. Tanaka S, et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg. 2008 May;95(5):611-9. [Content Brief]
- [4]. Pannone G, et al. Aurora B expression as a prognostic indicator and possible therapeutic target in oral squamous cell carcinoma. Int J Immunopathol Pharmacol. 2011 Jan-Mar;24(1):79-88. [Content Brief]
- [5]. Cao M, et al. A Vector-Based Short Hairpin RNA Targeting Aurora B Suppresses Human Prostatic Carcinoma Growth. Technol Cancer Res Treat. 2017 Feb;16(1):112-119. [Content Brief]
- [6]. Ryu J, et al. An Aurora kinase inhibitor, AMG900, inhibits glioblastoma cell proliferation by disrupting mitotic progression. Cancer Med. 2018 Nov;7(11):5589-5603. [Content Brief]
- [7]. Carmena M, et al. Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins. Curr Opin Cell Biol. 2009 Dec;21(6):796-805. [Content Brief]
- [8]. Sasai K, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton. 2004 Dec;59(4):249-63. [Content Brief]
- [9]. Li Z, et al. The Aurora Kinase in Trypanosoma brucei plays distinctive roles in metaphase-anaphase transition and cytokinetic initiation. PLoS Pathog. 2009 Sep;5(9):e1000575. [Content Brief]
- [10]. Meulenbeld HJ, et al. Danusertib, an aurora kinase inhibitor. Expert Opin Investig Drugs. 2012 Mar;21(3):383-93. [Content Brief]
-
Aurora B Related Products (80)
Related Products (80)
-
Antibodies (1)
-
SF-1
0 ImagesCat. No.: HY-168545Purity: 99.50%SF-1 is an AURKA ligand that can be used for the synthesis of PROTACs, such as PROTAC MPS1 degrader 2 (HY-168543). SF-1 can act as a free inhibitor and has the ability to pull down AURKA, AURKB, and TTK with DC50 values of 273.5, 933.5, and 1274 nM respectively. SF-1 has an anti-proliferative effect on acute myeloid leukemia.
-
Aurora kinase-IN-8
0 ImagesCat. No.: HY-175866CAS No.: 1911629-44-1Aurora kinase-IN-8 is a orally active Aurora kinase inhibitor. Aurora kinase-IN-8 shows IC50 values of 2.8 and 28.1 nM against Aurora A kinase and Aurora B kinase. Aurora kinase-IN-8 can prevent spindle formation, cause G2/M phase arrest, and induce cell apoptosis. Aurora kinase-IN-8 can be used for the research of cancer, such as triple-negative breast cancer.
-
Alisertib sodium
0 ImagesCat. No.: HY-10971ACAS No.: 1028486-06-7Synonyms: MLN 8237 sodiumAlisertib (MLN 8237) sodium is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib sodium induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity.
-
AT9283 lactic acid
0 ImagesCat. No.: HY-10058CAS No.: 896466-76-5
-
Aurora inhibitor 1
0 ImagesCat. No.: HY-111506CAS No.: 2227019-45-4
-
Aurora kinase/HDAC-IN-1
0 ImagesCat. No.: HY-179374CAS No.: 2727102-12-5Aurora kinase/HDAC-IN-1 is an orally active dual Aurora kinase and HDAC inhibitor that inhibits Aurora A (IC50 = 116 nM), Aurora B (IC50 = 225 nM), HDAC1 (IC50 = 164 nM), and HDAC2 (IC50 = 346 nM).Aurora kinase/HDAC-IN-1 promotes histone H3 acetylation, inhibits Aurora A phosphorylation and downstream signaling, and induces apoptosis via G2/M cell-cycle arrest. Aurora kinase/HDAC-IN-1 exhibits potent antiproliferative activity in colorectal cancer cells, with an IC50 value of 30.2 nM in HCT-116 cells.Aurora kinase/HDAC-IN-1 significantly suppresses tumor growth in an HCT-116 colorectal cancer xenograft mouse model.
-
Aurora kinase-IN-10
0 ImagesCat. No.: HY-181082CAS No.: 3053885-69-8Aurora kinase-IN-10 is an Aurora kinase inhibitor. Aurora kinase-IN-10 exhibits IC50 values of 5.94 nM and 86.06 nM against Aurora A and Aurora B, respectively. Aurora kinase-IN-10 has anti-tumor activity and can be used in the research of tumors such as triple-negative breast cancer.
-
LCI133
0 ImagesCat. No.: HY-179375CAS No.: 3065284-87-6LCI133 is afirst-in-class,nanomolar-potent, selective multikinase inhibitor targeting CDK4/6/9 and AURKA/B (IC50 = 4.7/10.2/4.1 nM and 2.8/10.6 nM). LCI133 induces S/G2 cell-cycle arrest and robust apoptosis in MYCN-amplified neuroblastoma BE(2)-C cells. LCI133 demonstrates significant antitumor efficacy in a BE(2)-C neuroblastoma xenograft model.
-
FAK-IN-22
0 ImagesCat. No.: HY-168718CAS No.: 2703920-02-7FAK-IN-22 (Compound 26) is an inhibitor of FAK, JAK3, and Aurora B, with IC50 values of 50.94 nM, 9.99 nM, and 0.49 nM, respectively, effectively inhibiting tumor occurrence and metastasis in pancreatic ductal adenocarcinoma (PDAC). FAK-IN-22 effectively inhibits the proliferation of PANC-1 cells, with an IC50 value of 0.15 μM. FAK-IN-22 induces apoptosis and G2/M phase arrest in PANC-1 cells by inhibiting the FAK/PI3K/Akt signaling pathway.
-
Aurora kinase inhibitor-14
0 ImagesCat. No.: HY-158618CAS No.: 958226-81-8Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of Aurora kinases with IC50 values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia.
-
Aurora A inhibitor 2
0 ImagesCat. No.: HY-146037CAS No.: 2412144-74-0Aurora A inhibitor 2 (Compound 16h) is a potent Aurora A kinase inhibitor with an IC50 of 21.94 nM. Aurora A inhibitor 2 induces caspase-dependent apoptosis in MDA-MB-231 cells.
-
CG-1521
0 ImagesCat. No.: HY-108919CAS No.: 674767-29-4CG-1521 is a histone deacetylase (HDAC) inhibitor that stabilizes Ac-Lys373 P53, increases P21 levels and HDAC2 degradation. CG-1521 can inhibit proliferation, induce cell cycle arrest and apoptosis. CG-1521 promotes Bax translocation to the mitochondria and cleavage. CG-1521 downregulates KIF4, Aurora B and Nek2 protein expression and DNA synthesis. CG-1521 can be used for the research of prostate cancer and inflammatory breast cancer.
-
SK4454
0 ImagesCat. No.: HY-179640SK4454 is a selective AURKA PROTAC degrader degrading AURKA with IC50 = 8 nM. MYCN levels in MYCN-amplified neuroblastoma cells and limited by MDR1-mediated efflux. SK4454 efficiently reduced AURKA levels in vivo. SK4454 can be used for neuroblastoma research.
-
IBPR002
0 ImagesCat. No.: HY-165369CAS No.: 1192754-38-3IBPR002 is an inhibitor of Aurora kinase A and Aurora kinase B, with IC50 values of 41 nM and 17 nM, respectively. IBPR002 disrupts the nucleation and bundling of kinetochore microtubules, impairs the bipolarity of mitotic spindles, and promotes the binding of non-phosphorylated hepatoma up-regulated protein (HURP) to microtubules derived from the mother centrosome. IBPR002 reduces tumorigenesis levels in a colorectal cancer xenograft model using athymic nude mice. IBPR002 is applicable for research related to colorectal cancer.
-
Aurora kinase/ALK-IN-1
0 ImagesCat. No.: HY-183767Aurora kinase/ALK-IN-1 is a dual Aurora A kinase and ALK inhibitor with IC50 values of 0.296 μM and 0.332 μM, respectively. Aurora kinase/ALK-IN-1 induces G2/M cell cycle arrest, triggers mitochondrial apoptosis, elevates intracellular reactive oxygen species (ROS) levels, and inhibits ALDH1 activity. Aurora kinase/ALK-IN-1 demonstrates cytotoxicity and tumor selectivity. Aurora kinase/ALK-IN-1 can be used for the research of anaplastic large cell lymphoma.
